大麻隆可减轻帕金森病非运动症状
这项在因斯布鲁克医科大学开展的II期安慰剂对照双盲随机撤药试验,纳入47例伴困扰性非运动症状(MDS-UPDRS-I≥4分)的帕金森病患者,先开放标签滴定大麻隆,应答者随机继续大麻隆或换用安慰剂4周。随机后第4周MDS-UPDRS-I变化安慰剂组为2.63(95%CI 1.53–3.74,P=0.002),大麻隆组为1.00(95%CI -0.16–2.16,P=0.280),组间差异1.63(95%CI 0.09–3.18,P=0.030)。
要点
- 大麻隆可能改善帕金森病伴困扰性非运动症状,效应主要来自焦虑情绪和夜间睡眠问题。
- 该研究为II期探索性试验,样本量小,结论需更大规模试验验证。
核心结论
- 大麻隆对伴困扰性非运动症状的帕金森病患者可能有效,其效果似乎由对焦虑情绪和夜间睡眠问题的正向作用驱动。
研究设计与样本
- II期安慰剂对照、双盲、平行组、富集入组随机撤药试验,在因斯布鲁克医科大学开展。
- 47例运动症状稳定且MDS-UPDRS-I≥4分的帕金森病患者先接受开放标签大麻隆滴定(0.25 mg每日一次至1 mg每日两次,I期)。
- 应答者按1:1随机继续大麻隆或换用安慰剂4周(II期),主要疗效指标为随机至第4周MDS-UPDRS-I变化。
- 安全性分析纳入所有至少接受一次大麻隆剂量的患者。
主要发现
- 第4周MDS-UPDRS-I平均变化:安慰剂组2.63(95%CI 1.53–3.74,P=0.002,效应量1.15),大麻隆组1.00(95%CI -0.16–2.16,P=0.280,效应量0.42)。
- 组间差异1.63(95%CI 0.09–3.18,P=0.030,效应量0.66)。
临床怎么用
- 对于伴困扰性非运动症状(MDS-UPDRS-I≥4分)且运动症状稳定的帕金森病患者,大麻隆可作为潜在治疗选择,但需关注不良事件。
- 治疗应答可能主要体现在焦虑情绪和夜间睡眠问题上,临床可据此评估疗效。
局限性
- 本研究为II期探索性试验,随机撤药阶段样本量仅19例,结论需更大规模试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to assess the efficacy and safety of nabilone, a synthetic tetrahydrocannabinol analogue, as a treatment for non-motor symptoms (NMS) in Parkinson's disease (PD). METHODS: This was a phase II placebo-controlled, double-blind, parallel-group, enriched enrollment randomized withdrawal trial conducted at the Medical University Innsbruck. A random sample of 47 patients with PD with stable motor disease and disturbing NMS defined by a score of ≥4 points on the Movement Disorder Society - Unified PD Rating Scale-I (MDS-UPDRS-I) underwent open-label nabilone titration (0.25 mg once daily to 1 mg twice daily, phase I). Responders were randomized 1:1 to continue with nabilone or switch to placebo for 4 weeks (phase II). The primary efficacy criterion was the change of the MDS-UPDRS-I between randomization and week 4. Safety was analyzed in all patients who received at least one nabilone dose. RESULTS: Between October 2017 and July 2019, 19 patients received either nabilone (median dose = 0.75 mg) or placebo. At week 4, mean change of the MDS-UPDRS-I was 2.63 (95% confidence interval [CI] 1.53 to 3.74, p = 0.002, effect size = 1.15) in the placebo versus 1.00 (95% CI -0.16 to 2.16, p = 0.280, effect size = 0.42) in the nabilone-group (difference: 1.63, 95% CI 0.09 to 3.18, p = 0.030, effect size = 0.66). Seventy-seven percent of patients had adverse events (AEs) during open-label titration, most of them were transient. In the double-blind phase, similar proportions of patients in each group had AEs (42% in the placebo group and 32% in the nabilone group). There were no serious AEs. INTERPRETATION: Our results highlight the potential efficacy of nabilone for patients with PD with disturbing NMS, which appears to be driven by positive effects on anxious mood and night-time sleep problems. TRIAL REGISTRY: ClinicalTrials.gov (NCT03769896) and EudraCT (2017-000192-86). ANN NEUROL 2020;88:712-722.
引用
- Peball M, Krismer F, Knaus HG, et al. Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. Ann Neurol. 2020. PMID: 32757413. doi:10.1002/ana.25864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。